MedWatch is the Food and Drug Administration’s (FDA) safety information and adverse event reporting program. It serves as a centralized system for healthcare professionals, patients, and consumers to report serious problems with medical products, including drugs, medical devices, and dietary supplements.
The program collects and analyzes these reports to identify potential safety issues and take appropriate action to protect public health. MedWatch also disseminates important safety information to healthcare providers and the public through various channels, including safety alerts and newsletters.
MedWatch plays a crucial role in clinical research by providing a standardized system for reporting adverse events and safety concerns. This centralized reporting mechanism allows researchers to monitor and evaluate the safety profiles of investigational drugs and medical devices throughout the clinical trial process and post-market surveillance.
The data collected through MedWatch can inform study protocols, help identify potential risks, and guide decision-making in clinical trials. Furthermore, MedWatch reports can contribute to the overall assessment of a product’s benefit-risk profile, which is essential for regulatory approvals and ongoing safety evaluations in clinical research.
We’re pleased to announce a strategic partnership between Axcellant and Prometheus MedTech.AI — a medtech startup developing AI-powered solutions for…
The Axcellant team has returned from the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona — and it’s…
The robust development of nuclear medicine depends on the availability of radioactive isotopes, some of which are used for diagnostic…
Copyright @ 2025 Axcellant